Abstract:

Objective　To investigate the clinical effect of montelukast sodium combined with mometasone furoate in patients with allergic rhinitis (AR). Methods　It was a prospective randomized controlled trial. Ninety-eight AR patients admitted to Weihai Central Hospital between July 2019 and July 2022 were randomly selected and were divided into two groups of forty-nine patients in each group by the random number table method. In the control group, 27 males and 22 females, aged (35.47±7.09) years, were treated with mometasone furoate; in the combination group, 23 males and 26 females, aged (36.85±7.37) years, were treated with mometasone furoate combined with montelukast sodium. The clinical effect, inflammation level, and adverse drug reactions were compared between the two groups. χ² test and t test were used. Results　The overall response rate of the combination group was 97.96% (48/49), which was significantly higher than that of the control group [83.67% (41/49)], with a statistically significant difference (χ²=4.404, P=0.036). Before treatment, there were no statistically significant differences in the levels of interleukin-4 (IL-4), intercellular adhesion molecule-1 (ICAM-1), and C-reactive protein (CRP) between the two groups (all P>0.05). After treatment, the levels of IL-4 [(115.43±12.83) ng/L], ICAM-1 [(5.74±1.15) μg/L], and CRP [(7.36±1.46) mg/L] in the combination group were significantly lower than those in the control group [(127.45±14.16) ng/L, (6.58±1.32) μg/L, and (8.41±1.68) mg/L], with statistically significant differences (all P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the combination group [10.20% (5/49)] and the control group [4.08% (2/49)] (χ²=0.615, P>0.05). Conclusion　The curative effect of montelukast sodium and mometasone furoate in the treatment of patients with AR is significantly improved, the level of inflammation is decreased, and the medication is safe.

Key words:

Allergic rhinitis, Mometasone furoate, Montelukast sodium

摘要：

目的　探究变应性鼻炎（AR）患者予以孟鲁司特钠与糠酸莫米松联合应用的临床效果。方法　本文为前瞻性随机对照试验。选取2019年7月至2022年7月威海市中心医院收治的AR患者98例为研究对象，采用随机数字表法将其分为两组，各49例。对照组男27例、女22例，年龄（35.47±7.09）岁，予以糠酸莫米松治疗；联合组男23例、女26例，年龄（36.85±7.37）岁，予以糠酸莫米松与孟鲁司特钠联合治疗。对比两组临床疗效、炎症水平及用药不良反应。采用χ²检验、t检验。结果　联合组总有效率为97.96%（48/49），明显高于对照组83.67%（41/49），差异有统计学意义（χ²=4.404，P=0.036）。治疗前，两组患者白细胞介素-4（IL-4）、细胞间黏附分子-1（ICAM-1）、C反应蛋白（CRP）水平比较，差异均无统计学意义（均P>0.05）；治疗后，联合组IL-4［（115.43±12.83）ng/L］、ICAM-1［（5.74±1.15）μg/L］、CRP水平［（7.36±1.46）mg/L］均明显低于对照组［（127.45±14.16）ng/L、（6.58±1.32）μg/L、（8.41±1.68）mg/L］，差异均有统计学意义（均P<0.05）。联合组不良反应发生率［10.20%（5/49）］与对照组［4.08%（2/49）］比较，差异无统计学意义（χ²=0.615，P>0.05）。结论　AR患者应用孟鲁司特钠与糠酸莫米松联合治疗，患者疗效显著提高，炎症水平下调，用药安全。

关键词:

变应性鼻炎, 糠酸莫米松, 孟鲁司特钠